Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~There are two subgroups of patients: Those undergoing autologous stem cell transplantation and those undergoing allogeneic stem cell transplantation.~Autologous transplant subgroup:~-Patients with the following hematologic malignancies (AML, CML, ALL, B cell malignancies, and myelodysplastic syndrome) who will be undergoing autologous stem cell transplantation.~Allogeneic transplantation subgroup:~-Patients with the following hematologic malignancies (AML, CML, ALL, B cell malignancies, and myelodysplastic syndrome) who have undergone allogeneic stem cell transplantation. There is no limitation on whether myeloablative or non-myeloablative chemotherapy is administered. A 3/6 or greater match is required for patients who have had an allogeneic stem cell transplant.~Both subgroups:~* Subject must be one of the following HLA types: HLA A2, A24, DR15 or DRw53 (includes HLA-DR4, -DR7, and DRw9)~* Karnofsky performance status must be greater than or equal to 70%.~* Age ≥ 18 years.~* Ability to understand and provide signed informed consent that fulfills Institutional Review Board guidelines.~* Patient must agree to use adequate contraception defined as: for women, one of the following (1) surgical sterilization, (2) approved hormonal contraceptives (such as birth control pills, Depo-Provera, or Lupron Depot), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD); for men, one of the following: (1) surgical sterilization, or (2) a condom used with a spermicide.~* In order to receive their immunizations, subjects should be:~For autologous transplants:~* At least 2 weeks from prior chemotherapy.~* Injections 1 and 2 must be completed prior to administration of any growth factor mobilization~* Injections 3, 4, 5, and 6, to resume 2 or more weeks from the time of their stem cell infusion if there has been no Grade 3 or 4 non-hematologic, major organ toxicity within the preceding 1 week. Non-major organ toxicities must have resolved to grade 2 or less.~For allogeneic transplants,~* At least 2 weeks from the time of their stem cell infusion.~* Without Grade 3 or 4 non-hematologic major organ toxicity within the preceding 1 week; non major organ toxicities must have resolved to grade 2 or less.~* We will require demonstration of \>50% donor myeloid hematopoiesis, based on microsatellite polymorphisms, prior to enrolling the patients with MDS on the study.~  * Adequate laboratory data as follows:~Hematologic function: WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (may transfuse or use erythropoietin to achieve this level), platelets ≥ 50,000/microliter ((may transfuse).~Renal and hepatic function: serum creatinine \< 1.5 mg/dL, bilirubin \< 1.5 mg/dL (except a bilirubin of \<2.0 will be permitted for patents with Gilbert's syndrome), SGOT/SGPT \< 2 x upper limit of normal.~* Subjects must have a CD4+ count is \> 200/mm. There is no specified requirement for CD8+ T cell count.~* Urine protein/creatinine ratio (UPC) must be less than 1.~Exclusion Criteria:~* Corticosteroid (greater than 10mg per day of prednisone or an equipotent dose of another corticosteroid) or other immunosuppressive therapy within the prior 1 week.~* Pregnant women and nursing mothers.~* Current or prior history of brain metastases.~* More than 12 months since their stem cell transplant.~* HIV +, hepatitis BsAg +, Hepatitis C Ab+.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A-WT1 derived peptides (Type: EXPERIMENTAL): Wilms' tumor gene 1 (WT1) derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg Granulocyte-macrophage colony-stimulating factor (GM-CSF) in a total volume of 2ml:~* WT peptide #1: (human leukocyte antigen) HLA-A2 restricted: RMFPNAPYL~* WT peptide #2: HLA-A24 restricted: CMTWNQMNL~* WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL~* WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT~Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues